Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
Patents for C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
11/2005
11/17/2005WO2005108379A1 Macrocycle-substituted trimer halogen-benzol derivatives
11/17/2005WO2005108368A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/17/2005US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
11/17/2005US20050256170 EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders
11/17/2005CA2568241A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/16/2005EP1594851A1 Trimeric macrocyclically substituted benzene derivatives
11/16/2005EP1594512A2 Compounds for the treatment of viral infection
11/15/2005CA2387517C Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
11/10/2005WO2005105770A2 Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
11/10/2005US20050250743 Ammonium salts of inositol hexaphosphate, and uses thereof
11/10/2005US20050247237 Carbon material
11/10/2005CA2562176A1 Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
11/09/2005EP1501787B1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists
11/09/2005CN1694875A 5-aryltetrazole compounds and uses thereof
11/08/2005CA2155104C Heterocyclic-substituted alkyl amide acat inhibitors
11/03/2005WO2005102987A1 Process for the preparation of valsartan and precursors thereof
11/03/2005US20050245602 Selective estrogen receptor modulators
11/03/2005US20050245534 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
11/03/2005US20050245525 Compounds useful for inhibiting CHK1
11/02/2005EP1590336A2 Substituted pyrazoles, compositions containing such compounds and methods of use
11/02/2005EP0988294B1 A process for the preparation of macrocyclic chelants and the chelates thereof with paramagnetic metal ions
11/02/2005CN1689969A 碳材料 Carbon Materials
11/02/2005CN1225471C Compounds with growth hormone releasing properties
11/01/2005US6960688 Use of compounds for the elevation of pyruvate dehydrogenase activity
11/01/2005US6960355 Modified amino acid compounds useful in delivery of active agents
10/2005
10/27/2005WO2004113275A3 Methods and compositions for treating amyloid-related diseases
10/27/2005US20050239836 Substituted hydroxyethylamine aspartyl protease inhibitors
10/27/2005US20050239790 Substituted hydroxyethylamine aspartyl protease inhibitors
10/27/2005US20050239051 Use of isogenic human cancer cells for high-throughput screening and drug discovery
10/26/2005EP1589000A2 (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
10/26/2005EP1587798A2 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
10/26/2005EP1183229B1 Glucagon antagonists/inverse agonists
10/26/2005CN1688556A Process for the manufacture of valsartan
10/26/2005CN1224598C Naphthalene derivatives
10/25/2005CA2304974C 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
10/25/2005CA2261725C Piperidine and piperazine derivatives and their use as muscarinic antagonists
10/25/2005CA2147056C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
10/20/2005WO2005097100A2 Antibacterial agents
10/20/2005US20050234109 to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine
10/20/2005US20050234016 Process for the preparation of adsorbates of valsartan and/or its solvates or hydrates
10/20/2005US20050233953 Histogranin-like peptides, processes for their preparation and uses thereof
10/20/2005CA2561741A1 Processes and reagents for oligonucleotide synthesis and purification
10/19/2005EP1586607A1 Carbon material
10/19/2005EP1586310A1 Method to manufacture valsartan adsorbates in the form of a free-flowing powder
10/19/2005EP1585955A2 Use of isogenic human cancer cells for high-throughput screening and drug discovery
10/19/2005EP1585511A2 Asthma and allergic inflammation modulators
10/15/2005CA2504551A1 Process for the preparation of adsorbates of valsartan and/or its solvates or hydrates
10/13/2005WO2005095334A1 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/13/2005WO2005095327A1 Aniline derivatives
10/13/2005WO2005094805A1 Imine derivative and amide derivative
10/13/2005WO2005041867A3 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3’(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline
10/13/2005WO2004113277A3 Methods and compositions for treating amyloid-related diseases
10/13/2005US20050227994 Decomposition inhibitor for extracellular matrix of cartilage
10/13/2005US20050227979 E.g., 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidine and 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane; these compounds modulate the activity of the histamine receptor, specifically the H3 receptor, without the inherent problems associated with the presence of an imidazolyl moiety
10/13/2005CA2562114A1 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/13/2005CA2557402A1 Pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
10/12/2005EP0814842B1 Method for treating amyloidosis
10/12/2005CN1680341A Valsartan salts
10/12/2005CN1680274A Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them
10/12/2005CN1679562A Antiviral compounds
10/11/2005US6953812 Carboxy and amide containing compound suitable for treatment and/or prevention of diseases wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, diabetes, disorders of the lipid metabolism, such as dyslipidemia
10/11/2005US6953792 Cyclohexyl derivatives and their use as therapeutic agents
10/06/2005WO2005020921A3 C-kit modulators and methods of use
10/06/2005US20050222426 A compound selected from the group consisting of 1,2,3-benzotriazol-2-yl-L-alanine, 5-carboxy-1,2,3-benzotriazol-2-yl-L-alanine, and 5-carboxy-1,2,3-benzotriazol-1-yl-L-alanine.
10/06/2005US20050222254 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/06/2005US20050222233 Preparing amorphous form of valsartan by precipitating amorphous valsartan from a solution of valsartan in a solvent selected from methyl ethyl ketone and ethyl acetate and recovering valsartan amorphous form without heating; use in treating hypertension
10/06/2005US20050222213 Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
10/06/2005US20050222146 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
10/06/2005US20050222137 Combination of organic compounds
10/06/2005DE102005011563A1 Preparation of dihydrazinium compounds of 5,5'-azotetrazolate type, used in propellant, pyrotechnic formulation, rocket fuel or gas-generating composition, involves reacting alkali metal azotetrazole and hydrazinium salt in aqueous medium
10/05/2005EP1581476A2 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors
10/05/2005EP1581470A1 2,6-dihalo-4-(3,3-dichloro-allyloxy)-benzylalcohole derivatives having insecticidal and acaricidal properties
10/05/2005EP1163231B1 Perfluoroalkylamide, the production thereof and the use thereof in diagnostics
10/05/2005CN1678573A Diarylurea derivatives and their use as chloride channel blockers
10/05/2005CN1678298A Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
10/05/2005CN1676523A Method for preparing antihypertension losartan
10/04/2005US6951639 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
09/2005
09/29/2005WO2005090298A1 Sulphonamide derivatives
09/29/2005WO2005090297A1 Sulphonamide derivatives
09/29/2005WO2004069196A3 Novel compounds
09/29/2005US20050215526 Melanin concentrating hormone receptor antagonist
09/29/2005CA2559919A1 Sulphonamide derivatives
09/28/2005CN1674892A Hetero biaryl derivatives as matrix metalloproteinase inhibitors
09/28/2005CN1674885A Methods for treatment and prevention of gastrointestinal conditions
09/28/2005CN1673219A Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them
09/28/2005CN1220683C Acyl derivatives for treating VLA-4 related disorders
09/27/2005US6949654 Treating diseases arising from reactive oxygen species and/or excess Zn ions, in particular stroke, Parkinson's disease and Alzheimer's disease.
09/27/2005US6949646 Nitrogen compounds such as 2-Butyl-1-(2-methylpropyl)-1H-tetrazolo[1,5-a]imidazo[4,5-c][1,8]naphthyridine, used to induce biosynthesis of cytokines such as interferons and tumor necrosis factors, or for prophylaxis of viral diseases
09/27/2005US6949537 LY294002 and analogs thereof comprising a reversibly quaternized amine; use of the pro-compounds for treatment of a condition associated with PI-3 kinase activity, including inflammatory disease, age-related macular degeneration, hypertension
09/22/2005WO2005087752A2 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005WO2005087751A2 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005WO2005087700A2 Bisphenyl compounds useful as vitamin d3 receptor agonists
09/22/2005WO2005087215A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
09/22/2005US20050209241 Benzoyl-piperazine derivatives
09/22/2005US20050209120 Use of transition metal complexes as bleach catalysts in laundry detergents and cleaning compositions
09/22/2005CA2558249A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
09/22/2005CA2558036A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2558034A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/21/2005EP1575964A2 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
09/21/2005EP1575495A2 Compounds and methods
1 ... 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 ... 97